Hospital Pharmacy Europe - Oncology,

Click here

Thursday 23 May 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here

LATEST ISSUE

Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses

Pharmacy Zone: Oncology

Magazine	Sponsored content
News	Video

Page:

1

Tue 21 May

Phase III trial of regorafenib in patients with advanced liver cancer
Bayer HealthCare has announced that the company has started to enrol patients in an international Phase III trial to evaluate the...

Tue 21 May

Phase III results for afatinib and ninedanib
Boehringer Ingelheim has announced the upcoming presentation of data from 14 abstracts involving three of the company’s...

Fri 17 May

Merck Serono: non-small cell lung cancer Phase III trial
Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomised Phase III START*...

Fri 17 May

Oncology portfolio
Bayer HealthCare has announced that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets,...

Fri 17 May

US FDA approval for cancer treatment Xofigo
Bayer HealthCare has announced that the US Food and Drug Administration (FDA) approved Xofigo® (radium 223 dichloride) for...

Mon 22 Apr

Fewer dry mouth symptoms with targeted irradiation
The use of targeted irradiation is enabling researchers at the University Medical Center (UMC) Utrecht to spare salivary glands...

Mon 22 Apr

Cost effective prostate cancer treatment
Better outcomes can be achieved for prostate cancer patients using brachytherapy, a highly targeted form of radiotherapy,...

Fri 12 Apr

Novel gene mutation identified that predisposes to testicular cancer
Researchers at the University Medical Center (UMC) Utrecht, the Netherlands, have identified a novel gene mutation that...

Wed 3 Apr

EFK Diagnostics focus on molecular and companion diagnostics
EKF Diagnostics, worldwide manufacturer of point-of-care diagnostic tools, organ injury biomarkers and assays, has announced the...

Tue 2 Apr

Practical clinical experience with bendamustine
Day-to-day, practical clinical experience with the unique alkylating agent, bendamustine, is discussed

Fri 22 Mar

CHMP positive opinion for new treatment for CML
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) has announced that the Committee for Human Medicinal Products (CHMP) of the European...

Wed 20 Mar

The Scottish Medicines Consortium accepts Picato®
Patients living in Scotland with actinic keratosis are one step closer to accessing Picato® (ingenol mebutate) gel following...

Tue 12 Mar

Benefits of Zyclara® for the treatment of actinic keratoses
Imiquimod 3.75% or 2.5% (Zyclara®) is a new, well-tolerated, topical treatment option for actinic keratoses of the face or...

Tue 12 Mar

Strategic alliance Menarini and Oxford BioTherapeutics
An innovative strategic alliance to develop a portfolio of antibody-based cancer drugs has secured Menarini and Oxford...

Mon 4 Mar

Rare Disease Day
With the enrolment of the first patient, Boehringer Ingelheim is pleased to announce on international Rare Disease Day, the...

Mon 25 Feb

Cilengitide fails to meet primary endpoint in patients with newly diagnosed glioblastoma
Merck Serono, a division of Merck, Darmstadt, Germany, has announced that the Phase III CENTRIC trial of the investigational...

Mon 25 Feb

Ablynx and Spirogen enter into a research collaboration
Ablynx and Spirogen Ltd. have announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate...

Fri 22 Feb

Bendamustine data published in The Lancet
Results from the StiL NHL-1 study published in The Lancet show that a first-line treatment regimen of bendamustine plus rituximab...

Wed 13 Feb

Priority review to NDA for the investigational oncology compound radium-223 dichloride
Bayer HealthCare announced today that the US Food and Drug Administration (FDA) has granted priority review to the New Drug...

Thu 31 Jan

Observational study suggests a role for Ferinject®
On the eve of World Cancer Day, Vifor Pharma notes the publication of an observational study in routine oncological and...

Page:

1

Web design, hosting and programming by ModeZero